Clinical Trial Update: Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating venetoclax in combination with CAG for refractory/relapsed acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CAG
• Venetoclax (venetoclax)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN